Faiva Edward, Hashim Hashim Talib, Ramadhan Mustafa Ahmed, Musa Shingin Kovona, Bchara John, Tuama Yahya Dheyaa, Adebisi Yusuff Adebayo, Kadhim Mustafa Hayder, Essar Mohammad Yasir, Ahmad Shoaib, Lucero-Prisno Don Eliseo
Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria, Nigeria.
College of Medicine, University of Baghdad, Baghdad, Iraq.
J Pharm Policy Pract. 2021 Jan 22;14(1):17. doi: 10.1186/s40545-021-00302-1.
The COVID-19 pandemic has resulted in massive disruptions in global supply chains. Nigeria is particularly vulnerable with respect to pharmaceuticals since there is reduced local production and about 70% of the drug supply is imported creating a huge supply-demand disparity particularly in times like COVID-19. Nigeria is in need of huge quantities of quality-assured health commodities to effectively respond to the pandemic. Significant shortages of other essential medicines and medical products across the country could be imminent. Drug scarcity in Nigeria during the COVID-19 pandemic period is because of several accumulated factors, majorly as a result of global lockdown, decreased manufacturing, unaddressed regulatory affairs, poor access to resources by the population, lack of buffer stocks, security instability, and poor funding of the healthcare system. This situation if left unattended, could cause serious drawbacks to the health of the populace as well as the quality of life of Nigerians amid the COVID-19 Pandemic. Appropriate measures should be directed to ensure ethical processes on drug production, importation, pricing, and distribution to avoid such events during unavoidable scenarios, like the COVID-19 pandemic and other public health emergencies.
新冠疫情导致全球供应链严重中断。尼日利亚在药品方面尤为脆弱，因为当地生产减少，约70%的药品供应依赖进口，这在新冠疫情这样的时期造成了巨大的供需差距。尼日利亚需要大量有质量保证的医疗用品，以有效应对疫情。全国各地其他基本药品和医疗产品可能即将出现严重短缺。新冠疫情期间尼日利亚药品短缺是多种因素累积所致，主要原因包括全球封锁、制造业下降、监管事务未得到解决、民众获取资源困难、缺乏缓冲库存、安全不稳定以及医疗系统资金不足。这种情况若不加以解决，在新冠疫情期间可能会给民众健康以及尼日利亚人的生活质量带来严重不利影响。应采取适当措施，确保药品生产、进口、定价和分销过程符合道德规范，以避免在诸如新冠疫情和其他突发公共卫生事件等不可避免的情况下出现此类情况。
